Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Direct Payment

$120,000.00

Evaluation of the role of ferroptosis in anti-melanoma immune responses

FY 2022-23

Summary
The last decade has witnessed a revolution in cancer therapy in which immune-based therapies have increased survival for a variety of cancers, including melanoma. However, ~50% of patients are resistant to therapy and die of disease. We aim to enhance immune-based therapies to improve patient survival. We believe that a recently described form of cellular death called "ferroptosis" may be a mechanism by which melanoma cells die when receiving immune therapy. Cell death by "ferroptosis" depends on iron metabolism. Our study seeks to find microscopic findings that are observed in melanomas that may predict response to immune therapies. We also seek to find gene expression markers that could predict this response. Our study aims to accomplish this in two ways. First, I will study the immune cells of melanoma that received immune therapy and look at their expression of genes related to ferroptosis. Second, having found target genes, I will develop tests using antibodies directed against the proteins expressed by these genes to identify the expression of protein in human tissue. These antibody-based tests could eventually be used as tests to predict which melanomas undergoing immune therapy might respond to therapy. This study will provide a framework to understand how ferroptosis works in the anti-melanoma immune response.
Program
CIHR Fellowship
Location
Connecticut, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
472166
Name
Roy Simon F
Region
Connecticut
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Evaluation of the role of ferroptosis in anti-melanoma immune responses
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Anti-Cancer Immune Response; Ferroptosis; Immunology; Melanoma
Abstract
The last decade has witnessed a revolution in cancer therapy in which immune-based therapies have increased survival for a variety of cancers, including melanoma. However, ~50% of patients are resistant to therapy and die of disease. We aim to enhance immune-based therapies to improve patient survival. We believe that a recently described form of cellular death called "ferroptosis" may be a mechanism by which melanoma cells die when receiving immune therapy. Cell death by "ferroptosis" depends on iron metabolism. Our study seeks to find microscopic findings that are observed in melanomas that may predict response to immune therapies. We also seek to find gene expression markers that could predict this response. Our study aims to accomplish this in two ways. First, I will study the immune cells of melanoma that received immune therapy and look at their expression of genes related to ferroptosis. Second, having found target genes, I will develop tests using antibodies directed against the proteins expressed by these genes to identify the expression of protein in human tissue. These antibody-based tests could eventually be used as tests to predict which melanomas undergoing immune therapy might respond to therapy. This study will provide a framework to understand how ferroptosis works in the anti-melanoma immune response.
Competitiondate
202210
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Roy, Simon F
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~
Direct Payment - $120,000 Grant (2022-23) | Canada Spends